

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/051,767	01/17/2002	Gopal Thinakaran	ARCD:364US/MBW	5574
7590 09/29/2004			EXAMINER	
Priya D. Subramony Fulbright & Jaworski L.L.P.			LOCKARD, JON MCCLELLAND	
Suite 2400			ART UNIT	PAPER NUMBER
600 Congress Avenue AUSTIN, TX 78701			1647	
			DATE MAILED: 09/29/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)
Office Action Summary		10/051,767	THINAKARAN, GOPAL
		Examiner	Art Unit
		Jon M Lockard	1647
The MAILING DATE of this Period for Reply	communication ap	ppears on the cover sheet w	vith the correspondence address
Any reply received by the Office later than the earned patent term adjustment. See 37 CFF	OMMUNICATION ne provisions of 37 CFR 1 of this communication, than thirty (30) days, a remaximum statutory period for reply will, by statures months after the mail	136(a). In no event, however, may a ply within the statutory minimum of this will apply and will expire SIX (6) MON to cause the application to become	reply be timely filed rty (30) days will be considered timely. NTHS from the mailing date of this communication.
Status			
1) Responsive to communicat	ion(s) filed on	·	
2a)☐ This action is FINAL .	2b)⊠ Thi	s action is non-final.	
3) Since this application is in c	condition for allowa	ance except for formal mat	ters, prosecution as to the merits is
closed in accordance with t	he practice under	Ex parte Quayle, 1935 C.D). 11, 453 O.G. 213.
Disposition of Claims			
4)⊠ Claim(s) <u>1-51</u> is/are pending	g in the application	١.	
4a) Of the above claim(s)			
5) Claim(s) is/are allow	ed.		
6)☐ Claim(s) is/are reject			
7) Claim(s) is/are objec			
8)⊠ Claim(s) <u>1-51</u> are subject to	restriction and/or	election requirement.	
pplication Papers			
9) The specification is objected	to by the Examine	ar	
10) The drawing(s) filed on			ov the Evaminer
Applicant may not request that	any objection to the	drawing(s) be held in abevan	ce. See 37 CFR 1.85/a)
Replacement drawing sheet(s)	including the correct	tion is required if the drawing	(s) is objected to. See 37 CFR 1.121(d).
11) The oath or declaration is ob	jected to by the Ex	kaminer. Note the attached	Office Action or form PTO-152.
riority under 35 U.S.C. § 119			
•			
12) Acknowledgment is made of a) All b) Some * c) No		priority under 35 U.S.C. §	119(a)-(d) or (f).
1. Certified copies of the		s have been received	
2. Certified copies of the	priority document	s have been received. S have been received in Ar	onligation No
3. Copies of the certified	copies of the prior	ity documents have been a	received in this National Stage
application from the In	ternational Bureau	(PCT Rule 17.2(a))	eceived in this National Stage
* See the attached detailed Office			eceived
tachment(s) Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing F	Parism (PTO 040)	4) Interview Su	ummary (PTO-413)
☐ Information Disclosure Statement(s) (PTC	0-1449 or PTO/SB/08)	5) Notice of Inf	/Mail Date ormal Patent Application (PTO-152)
Paper No(s)/Mail Date	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	6) 🔲 Other:	

Art Unit: 1647

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-6 and 13-51, in so far as they are drawn to methods of identifying candidate substances that change the levels of accumulation of presentilin 1 (PS1) protein, classification dependent upon compound structure.
- II. Claims 1-5, 7, and 13-51, in so far as they are drawn to methods of identifying candidate substances that change the levels of accumulation of presentilin 2 (PS2) protein, classification dependent upon compound structure.
- III. Claims 1-4, 13-36, and 38-42, in so far as they are drawn to methods of identifying candidate substances that change the levels of accumulation of an amyloid precursor protein and amyloid precursor protein derivatives, classification dependent upon compound structure.
- IV. Claims 1-2, 8-11, 13-23, and 34, in so far as they are drawn to methods of identifying candidate substances that change the levels of accumulation of a nicotinic acetylcholine receptor protein, classification dependent upon compound structure.
- V. Claims 1-2, 8-11, and 13-34, in so far as they are drawn to methods of identifying candidate substances that change the levels of accumulation of a GABA receptor protein, classification dependent upon compound structure.

Art Unit: 1647

- VI. Claims 1-2, 8-11, and 13-34, in so far as they are drawn to methods of identifying candidate substances that change the levels of accumulation of a glycine receptor protein, classification dependent upon compound structure.
- VII. Claims 1-2, 8-10, and 12-34, in so far as they are drawn to methods of identifying candidate substances that change the levels of accumulation of a voltage-gated sodium channel protein, classification dependent upon compound structure.
- VIII. Claims 1-2, 8-10, and 12-34, in so far as they are drawn to methods of identifying candidate substances that change the levels of accumulation of a voltage-gated potassium channel protein, classification dependent upon compound structure.
- IX. Claims 1-2, 8-10, and 12-34, in so far as they are drawn to methods of identifying candidate substances that change the levels of accumulation of a voltage-gated calcium channel protein, classification dependent upon compound structure.

The inventions are distinct, each from the other because of the following reasons:

The various methods of Inventions I-IX are drawn to patentably distinct methods. Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for Inventions that are directed to <u>different</u> methods, restriction is deemed to be proper because these methods appear to constitute patentably distinct inventions for the following reasons: The methods of Inventions I-IX are separate and distinct, each one from the other, as they utilize different starting materials, method steps, and require different outcomes and non-coextensive searches.

Art Unit: 1647

Therefore, a search and examination of all the methods of Inventions I-IX in one patent application would result in an undue burden, sense the searches for the Inventions' methods are not co-extensive.

Election of Species

In addition to the above Restriction requirement, a further election of species is required as follows:

If applicant elects any one of Inventions I-IX:

This application contains claims directed to the following patentably distinct species of the claimed invention: Claims 26-34 and 38-51 encompass several marker gene products: fluorescent gene product, yellow fluorescent protein, green fluorescent protein, blue fluorescent protein, red fluorescent protein, antibiotic resistant gene product, bleomycin resistance gene product, zeocin resistance gene product, zorbamycin resistance gene product, victomycin resistance gene product, platomycin resistance gene product, tallysomycin resistance gene product, SF 1771 resistance gene product, SF 1961 resistance gene product, and a YA 56 resistance gene product. Applicants are required to designate a single, ultimate species to be searched.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species of marker gene products for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-25 and 35-37 are generic with regards to the marker gene product.

Furthermore, if applicant elects any one of Inventions I-IX:

Art Unit: 1647

This application contains claims directed to the following patentably distinct species of the claimed invention: Claims 15-22 encompass several candidate substances: chemical compounds, protein, protein candidate substances, pharmacological compounds, and nucleic acids. Applicants are required to designate a single, ultimate species to be searched.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species of candidate substances for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-14, 18, and 23-51 are generic with regards to the candidate substance.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the

Art Unit: 1647

examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1647

Conclusion

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Jon M. Lockard, Ph.D. whose telephone number is (571) 272-

2717. The examiner can normally be reached on Monday through Friday, 8:00 AM to 6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor,

Brenda Brumback, Ph.D. can be reached on (571) 272-0961.

The fax number for the organization where this application or proceeding is assigned is 703-

872-9306.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private

PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

JML

September 16, 2004

PERVISORY PATENT EXAMINER

Page 7

TECHNOLOGY CENTER 1600